TABLE OF CONTENTS
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of: January, 2008
Commission File Number: 000-50393
NEUROCHEM INC.
275 Armand-Frappier Boulevard
Laval, Québec
H7V 4A7
Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40 F.
Form 20-F
¨
Form 40-F
þ
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
Yes
¨
No
þ
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):
Yes
¨
No
þ
Indicate by check mark whether the registrant by furnishing the information contained in this Form
is also thereby furnishing the information to the Commission pursuant to Rule 12g-3 under the
Securities Exchange Act of 1934.
Yes
¨
No
þ
If Yes is marked, indicate below the file number assigned to the registrant in connection with
Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
NEUROCHEM INC.
|
|
January 3, 2008
|
|
|
|
By:
|
/s/ Lise Hébert, Ph.D.
|
|
|
|
Lise Hébert, Ph.D.
|
|
|
|
Vice President, Corporate Communications
|
|
|
For further information, please contact:
|
|
|
Lise Hébert, PhD
Vice President, Corporate Communications
|
|
Tel: (450) 680-4570
lhebert@neurochem.com
|
NEUROCHEM TO PRESENT AT
JPMORGAN HEALTHCARE CONFERENCE
LAVAL, QUEBEC, January 3, 2008
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces today that on
Thursday, January 10, 2008, Dr. Francesco Bellini, Chairman, President and CEO, will present
Neurochems overall strategy at the 26
th
Annual JPMorgan Healthcare Conference to be
held at the Westin St. Francis Hotel, in San Francisco (CA). The presentation will take place at
2:00 P.M. PST, in the Elizabethan A & B room.
About Neurochem
Neurochem Inc. is a global health company focused on the research, development and
commercialization of products to provide innovative health solutions to patients suffering from
serious diseases.
To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North
American toll-free number
1-877-680-4500 or visit our Web Site at www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are
independently verifiable at the date hereof, may constitute forward-looking statements. Such
statements, based as they are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem Inc.s
control. Such risks include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory
environment in the jurisdictions in which the Neurochem group does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment due to consolidation,
that actual results may vary once the final and quality-controlled verification of data and
analyses has been completed, as well as other risks disclosed in public filings of Neurochem Inc.
Consequently, actual future results may differ materially from the anticipated results expressed in
the forward-looking statements. The reader should not place undue reliance, if any, on any
forward-looking statements included in this news release. These statements speak only as of the
date made and Neurochem Inc. is under no obligation and disavows any intention to update or revise
such statements as a result of any event, circumstances or otherwise. Please see the Annual
Information Form of Neurochem Inc. for further risk factors that might affect the Neurochem group
and its business.